EXPANSION OF INDICATIONS FOR BOTULINUM TOXIN TYPE A PREPARATION (ABOBOTULINUMTOXIN A): THE OPTIMAL APPROACH TO THE SELECTION OF TARGETED MUSCLES AND CALCULATION OF DOSES WITH THE SPASTIC FORMS OF INFANTILE CEREBRAL PALSY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article deals with the problem of a multilevel approach to injection of botulinum toxin type A (BTA) preparations to correct spasticity in infantile cerebral palsy (ICP). Through the example of Abobotulinumtoxin A, for which extended indications for use in ICP patients have been obtained in 2017, an optimal approach to the choice of targeted muscles, the calculation of the total dose per procedure and dose for each muscle and injection site, are discussed, as well as the need for repeated injections, the optimal intervals between injections and other aspects, taking into account the child body weight, the degree of spasticity, and the level of development of motor skills. Also, the article presents two clinical observations as examples of determining indications for injecting Abobotulinumtoxin A and choosing the optimal scheme.

Full Text

Restricted Access

About the authors

A. L Kurenkov

National Medical Research Center for Children's Health

Email: alkurenkov@gmail.com
MD, Neurologist, Leading Scientist

O. A Klochkova

National Medical Research Center for Children's Health

B. I Bursagova

National Medical Research Center for Children's Health

L. M Kuzenkova

National Medical Research Center for Children's Health

A. M Mamedyarov

National Medical Research Center for Children's Health

L. A Pack

National Medical Research Center for Children's Health

References

  1. Graham H.K., Rosenbaum P., Paneth N., et al. Cerebral palsy. Nat. Rev. Dis. Primers. 2016;2:15082. doi: 10.1038/nrdp.2015.82.
  2. Cerebral palsy: A Multidisciplinary Approach. 3rd edition (ed. C.P. Panteliadis). Cham: Springer, 2018. 358 p.
  3. Strobl W., Theologis T., Brunner R., et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629-48. doi: 10.3390/toxins7051629.
  4. Delgado M.R., Hirtz D., Aisen M., et al. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-43. Doi.org/10.1212/WNL.0b013 e3181cbcd2f.
  5. Куренков А.Л., Клочкова О.А., Змановская В.А. и др. Первый Российский консенсус по применению многоуровневых инъекций Abobotulinumtoxin A при лечении спастических форм детского церебрального паралича. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;11(116):121-30. Doi. org/10.17116/jnevro20161 161 1 1 121-130.
  6. Baker R., Jasinski M., Maciag-Tymecka i., et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebocontrolled, dose-ranging study. Dev. Med. Child Neurol. 2002;44(10):666-75.
  7. Kanovsky P., Bares M., Severa S., Richardson A.; Dysport Paediatric Limb Spasticity Study Group. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev. Med. Child Neurol. 2009;51(6):436-45. doi: 10.1111/j.1469-8749.2008.03264.x.
  8. Клочкова O.A., Куренков А.Л., Каримова Х.М. и др. Многоуровневые инъекции ботулинического токсина типа А. (Абоботулотоксина) при лечении спастических форм детского церебрального паралича: ретроспективное исследование опыта 8 российских центров. Педиатрическая фармакология. 2016;13(3):259-69. doi: 10.15690/pf.v13i3.1576.
  9. Heinen F., Desloovere K., Schroeder A.S., et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol. 2010;14:45-66. Doi.Org/10.1016/J. Ejpn.2009.09.005.
  10. Love S.C., Novak I., Kentish M., et al.; Cerebral Palsy institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur. J. Neurol. 2010;17(Suppl. 2):9-37. doi: 10.1111/j.1468-1331.2010.03126.x.
  11. Delgado M.R., Tilton A., Russman B., et al. Abobotulinumtoxin A for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics. 2016;137(2):e20152830. doi: 10.1542/peds.2015-2830.
  12. Delgado M.R., Bonikowski M., Carranza J., et al. Safety and efficacy of repeat open-label AbobotulinumtoxinA treatment in pediatric cerebral palsy. J. Child Neurol. 2017;32(13):1058-64. doi: 10.1177/0883073817729918.
  13. Tilton A., Russman B., Aydin R.,etal.AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J. Child Neurol. 2017;32(5):482-87. doi: 10.1177/0883073816686910.
  14. Mall V., Heinen F., Siebel A., et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev. Med. Child Neurol. 2006;48(1):10-3. Doi: 10.1017/ S0012162206000041.
  15. Hägglund G., Wagner P Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet Disord. 2008;9:150. doi: 10.1186/1471-2474-9-150.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies